Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 06 May 2015 | By Michael Mezher
Members of scientific and expert committees at the European Medicines Agency (EMA) will no longer be able to take part in the evaluation of medicines if they intend to work for a pharmaceutical company.
In 2012, EMA came under fire from the European Court of Auditors (ECA), after an audit uncovered a number of shortfalls in the agency's conflict of interest (COI) policies.
At the time, ECA made recommendations to EMA intended to improve the agency's COI policies and their implementation. The recommendations included pre-screening candidates for COI before appointment and making declaration of interest (DOI) processes more transparent.
ECA also highlighted the need for EMA to address post-employment issues following the controversy surrounding the agency's former Executive Director Thomas Lönngren, who began consulting for the pharmaceutical industry weeks after leaving the agency. Critics contended that EMA failed to uphold EU staff regulations and expressed concern that Lönngren's working knowledge of policies being developed by the agency could "influence the outcome" of the policies.
In response to ECA's recommendations, EMA held a public consultation and workshop on improving its COI operations and policies.
These efforts led to the development of a Best Practice Guide for Staff leaving the Agency in 2013, and a new COI policy, which came into effect on 30 January 2015.
The Best Practice Guide reminds EMA staff of their obligation to "inform the agency of their intention to engage in an occupational activity whether gainful or not … for a two year period following their departure." Additionally, if a current staff member plans on taking a job following their departure from EMA, the agency can restrict them from certain product-related activities.
The new COI policy, EMA/626261/2014, Corr. 1, deals with how the agency handles declarations of interest for its scientific and expert committee members. The policy also introduces a three-tiered system for ranking declared interests, which range from "no interests declared" at level 1 to "direct interests declared" at level 3.
Now, several months after the policy went into effect, EMA has decided it needs to further explain one particular clause, which states:
“Furthermore, if a scientific committee/working party/SAG/ad hoc expert group member intends to be engaged (either solicited or not) in occupational activities with a pharmaceutical company (such as employment) during the term of the mandate, the member shall immediately inform the Agency and refrain from any activities which may have an impact on the pharmaceutical company concerned, and shall comply with any additional conditions or limitations which the Agency may consider appropriate to impose.”
In a new guidance document, EMA clarifies that it is taking a broad interpretation of this clause. Rather than barring committee members from participating in activities which relate to their future employers, EMA says it will "fully restrict the member or alternative immediately from further involvement in any Agency activity from the date of notification.” The agency says it will also conduct a review to "verify the integrity" of any ongoing or past evaluations the member was party to.
EMA Press Release
Tags: Conflict of interest, COI, declared interests
Regulatory Focus newsletters
All the biggest regulatory news and happenings.